177 related articles for article (PubMed ID: 26982261)
1. Deciphering the mechanism behind the varied binding activities of COXIBs through Molecular Dynamic Simulations, MM-PBSA binding energy calculations and per-residue energy decomposition studies.
Chaudhary N; Aparoy P
J Biomol Struct Dyn; 2017 Mar; 35(4):868-882. PubMed ID: 26982261
[TBL] [Abstract][Full Text] [Related]
2. Toward the understanding of the molecular basis for the inhibition of COX-1 and COX-2 by phenolic compounds present in Uruguayan propolis and grape pomace.
Paulino M; Alvareda E; Iribarne F; Miranda P; Espinosa V; Aguilera S; Pardo H
J Biomol Struct Dyn; 2016 Dec; 34(12):2643-2657. PubMed ID: 26610257
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms in the Selectivity of Nonsteroidal Anti-Inflammatory Drugs.
Shamsudin Y; Gutiérrez-de-Terán H; Åqvist J
Biochemistry; 2018 Feb; 57(7):1236-1248. PubMed ID: 29345921
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
5. Application of per-residue energy decomposition to identify the set of amino acids critical for
Chaudhary N; Aparoy P
Heliyon; 2020 Oct; 6(10):e04944. PubMed ID: 33083581
[TBL] [Abstract][Full Text] [Related]
6. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.
Rimon G; Sidhu RS; Lauver DA; Lee JY; Sharma NP; Yuan C; Frieler RA; Trievel RC; Lucchesi BR; Smith WL
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):28-33. PubMed ID: 19955429
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R; Azizi E; Daraie B; Hedayati M; Dadrass OG
Bioorg Med Chem; 2009 Jul; 17(14):5312-7. PubMed ID: 19560931
[TBL] [Abstract][Full Text] [Related]
8. COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles.
Oniga SD; Pacureanu L; Stoica CI; Palage MD; Crăciun A; Rusu LR; Crisan EL; Araniciu C
Molecules; 2017 Sep; 22(9):. PubMed ID: 28891941
[TBL] [Abstract][Full Text] [Related]
9. MM-PBSA and per-residue decomposition energy studies on 7-Phenyl-imidazoquinolin-4(5H)-one derivatives: Identification of crucial site points at microsomal prostaglandin E synthase-1 (mPGES-1) active site.
Gupta A; Chaudhary N; Aparoy P
Int J Biol Macromol; 2018 Nov; 119():352-359. PubMed ID: 30031079
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.
Yamakawa N; Suzuki K; Yamashita Y; Katsu T; Hanaya K; Shoji M; Sugai T; Mizushima T
Bioorg Med Chem; 2014 Apr; 22(8):2529-34. PubMed ID: 24650702
[TBL] [Abstract][Full Text] [Related]
11. The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.
Shukla S; Bafna K; Sundar D; Thorat SS
PLoS One; 2014; 9(6):e90637. PubMed ID: 24603686
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided, rational design of a potent and selective small peptide inhibitor of cyclooxygenase 2 (COX2).
Rajakrishnan V; Manoj VR; Subba Rao G
J Biomol Struct Dyn; 2008 Apr; 25(5):535-42. PubMed ID: 18282008
[TBL] [Abstract][Full Text] [Related]
13. Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs.
Dileep KV; Remya C; Tintu I; Sadasivan C
J Biomol Struct Dyn; 2014; 32(11):1855-63. PubMed ID: 24053423
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of rofecoxib bound to human cyclooxygenase-2.
Orlando BJ; Malkowski MG
Acta Crystallogr F Struct Biol Commun; 2016 Oct; 72(Pt 10):772-776. PubMed ID: 27710942
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Abdel-Aziz AA; ElTahir KE; Asiri YA
Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R
Bioorg Med Chem; 2010 Aug; 18(16):5855-60. PubMed ID: 20650641
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anti-inflammatory activity and molecular docking studies of 2,5-diarylfuran amino acid derivatives.
Stefani HA; Botteselle GV; Zukerman-Schpector J; Caracelli I; da Silva Corrêa D; Farsky SH; Machado ID; Santin JR; Hebeda CB
Eur J Med Chem; 2012 Jan; 47(1):52-8. PubMed ID: 22071254
[TBL] [Abstract][Full Text] [Related]
18. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Ouellet M; Riendeau D; Percival MD
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14583-8. PubMed ID: 11717412
[TBL] [Abstract][Full Text] [Related]
19. Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
Bhardwaj A; Kaur J; Wuest F; Knaus EE
ChemMedChem; 2014 Jan; 9(1):109-16, 240. PubMed ID: 24376205
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking, molecular modeling, and molecular dynamics studies of azaisoflavone as dual COX-2 inhibitors and TP receptor antagonists.
Hadianawala M; Mahapatra AD; Yadav JK; Datta B
J Mol Model; 2018 Feb; 24(3):69. PubMed ID: 29480373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
